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D

John H. Gibbon Jr., MD

r. John Heysham Gibbon, Jr. graduated from Jefferson Medical College in 1927, and after an internship at Pennsylvania Hospital, began a research fellowship at Massachusetts General Hospital. In 1930, he
found himself assisting Dr. Edward Churchill in an emergency pulmonary embolectomy. At that time, the procedure was one of desperation,
as no patient in the U.S. had survived the removal of blood clots in openheart surgery. As Dr. Gibbon recorded the patient’s waning vital signs
prior to the procedure, he thought, “If only we could remove the blood
from her body by bypassing her lungs, and oxygenate it, then return it to
her heart, we could almost certainly save her life.” Despite a successful
removal of large clots from the patient’s pulmonary artery, the patient
never regained consciousness. This “critical event” initiated Dr. Gibbon’s
determination to produce a heart-lung machine.
Dr. Gibbon was Chief of Surgical Services at the 364th Station Hospital
in the Pacific Theater. After the war, upon returning to Philadelphia, his
alma mater offered him the position of Professor of Surgery and Director of Surgical Research, which he accepted. Through Jefferson Medical
College’s connections, IBM and its premier engineering department entered the picture and worked with Dr. Gibbon
to develop a device known as IBM “Model I.” His wife, Maly Gibbon, and the Jefferson Medical College surgical residents were also deeply involved in the evolution of this huge apparatus (too heavy for the building’s elevators), which
proved to be successful in repeated experiments on dogs. However, limitations on the machine for human patients
existed and the decision was made to cannibalize parts of Model I for Model II, which was ready for its first test in February 1952. Although the heart-lung device was fully functional, the first patient, a 15-month-old child, died during
the operation. The defect, in this case, was much larger than the surgeons had been prepared for.
On May 6, 1953, at Jefferson Medical College Hospital, Dr. Gibbon and his
staff, with the help of his latest-designed heart-lung machine, “Model II,” closed
a very serious atrial septal defect between the upper chambers of the heart of
18-year-old Cecelia Bavolek. This was the first successful intra-cardiac surgery
of its kind performed on a human patient. “Jack” Gibbon did not follow this
epoch-making event by holding an international press conference
or by swiftly publishing his achievements in a major medical journal. According to a recent biographical review by C. Rollins Hanlon, “Therein lies a hint
of the complex, unassuming personality behind the magnificent technical and
surgical achievement of this patrician Philadelphia surgeon.” After the triumphant Bavolek case in May of 1953, Dr. Gibbon employed the Model II on two
more patients in July 1953. Both children subsequently died, prompting Gibbon to declare a year’s moratorium regarding use of the heart-lung machine,
pending investigations into solving clotting problems and blood loss.
During the years leading up to his successful surgery, Dr. Gibbon had been
sharing his blueprints and experiences with Dr. John Kirklin at The Mayo Clinic. Eventually, the Mayo Clinic built the “Model III” based on the proposed
changes from Dr. Gibbon’s lab, which led to several successful operations there.
While Dr. Gibbon turned to his non-cardiac interests, others continued to perfect cardiac surgery. It is clear that Dr. Gibbon’s contributions to the field of
cardiac surgery were necessary in order for the field to develop, which is why
he is often referred to the “father of cardiac surgery.”
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A History of ECMO and its Use During the
COVID-19 Pandemic

By Michelle Schafer, Class of 2024
REVIEWS

T

hroughout the COVID-19 pandemic, extracorporeal membrane oxygenation (ECMO) has emerged as a treatment
for patients suffering from severe respiratory distress as a
temporary solution to bypass the lungs and heart in favor of
a mechanical oxygenator. Although the earliest versions of
ECMO were developed in the 1950s and 1960s, the popularity
of ECMO as a ICU treatment of last resort is recent, and is
largely due to its success during the H1N1 influenza pandemic.
However, ECMO use comes with a fair share of adverse risks,
which should be thoroughly evaluated when its use is considered in the management of patients with severe COVID-19.
ECMO is designed to be a mechanical device that can
function as an external artificial cardiopulmonary system. Deoxygenated blood from a large vein, such as the femoral, internal jugular, or subclavian, is pumped out of the body through
tubing to a membrane oxygenator. The subsequent gas diffusion occurs on this membrane similarly to how it would in the
alveoli, which acts to both oxygenate and remove carbon dioxide from the blood. Venovenous (VV) ECMO returns blood
back to the venous system and acts as lung support, while venoarterial (VA) ECMO provides respiratory and hemodynamic support for the patient. In the 1950s, clinicians attempted
to use the cardiopulmonary bypass machine as a form of life
support in patients with acute cardiac or respiratory failure.
Unfortunately, the bypass machine exposed the blood directly to oxygen, which induced both hemolysis and protein denaturation and caused major complications. Subsequently,
clinicians began to study technologies that could externally
oxygenate blood. Earlier attempts included the use of various
plastic films as well as modified methods of hemodialysis, and
had limited success. Doctors at Pacific Medical Center in San
Francisco, California, had a 100% mortality rate in the patients
that received treatment from their version of an ECMO machine from 1966-1970.1 A metanalysis paper published shortly
thereafter determined that survival rates in Acute Respiratory
Distress Syndrome (ARDS) patients receiving ECMO were
similar to outcomes from time-period conventional ventilation,
with both producing similarly high mortality rates— 90.5% in
ECMO patients and 91.7% in conventional ventilation.1 This
paper stalled ECMO research for some time due to the lack
of difference in mortality, as well as the continuing obstacles
faced in finding the appropriate anticoagulation necessary to
allow the oxygenator to function properly without leading to
adverse hemorrhagic events.
In 1971, Pacific Medical Center had their first successful case of a patient with acute respiratory distress syndrome
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(ARDS) using peripheral VA-ECMO with a Bramson membrane heart-lung machine. The patient was successfully weaned
off the machine after 72 hours and discharged. In the following
years and decades, additional cases of successful ECMO use
were reported in both ARDS and neonatal respiratory failure.1
In 2009, many patients hospitalized during the H1N1 influenza
pandemic received ECMO therapy and were found to have improved six month survival rates.2, 3 Subsequently in the 2010s,
ECMO was seen as an emerging technology for other cardiopulmonary pathologic presentations, such as cardiac arrest and
shock. Unfortunately, hemorrhagic, neurologic, and other significant complications were still being observed in high rates.2
ECMO has been used in the treatment of ARDS since its
origination. Traditional ARDS is driven by release of proinflammatory cytokines, which ultimately leads to a protein-rich
fluid accumulation in the alveoli and to decreased ability of the
alveoli to ventilate the blood in the pulmonary circuit. In an
early case series published in the Journal of Cardiac Surgery in
2020, VV-ECMO failure in a small population of hypercoagulable patients was found to stem from thrombi states causing
oxygenator dysfunction.4 This case report was one of many at
the time that allowed physicians and scientist to realize that
the ARDS seen in COVID-19 patients was unique. COVID-19
has been observed to cause a hypercoagulable state in some
patients, which can result in microthrombi and damage to vessel endothelium causing decreased perfusion, mimicking the
physiology of pulmonary emboli.5
The slightly altered pathophysiology of COVID-related
ARDS warranted a novel name, leading to the term COVID-19
acute respiratory distress syndrome (CARDS).6 Importantly,
recognizing CARDS as unique from traditional ARDS led
to changes and improvements in care. Many patients with
CARDS developed hypoxemic and hypercapnic states, leading
to a decision early in the pandemic to intubate and mechanically ventilate patients as promptly as possible; however, there
was increasing potential for ventilation-induced lung injury
and oxidative stress in these patients.2 Resistant hypoxemia
and hypercapnia lead to some patients being placed on ECMO,
yet these patients were still susceptible to mechanical lung
damage.6 ECMO also presented challenges with increased
dead space and greater carbon dioxide retention. Moreover,
ECMO use is not without consequences, so physiotherapy and
rehabilitative activities were exceedingly important in patients
recovering from any ECMO use.6
The recency of ECMO as a widely adapted technology allowed for recommended use early in the COVID-19 pandemic

Figure 1: A) VV ECMO, femoral cannulation B) VA ECMO, femoral cannulation C) VA ECMO, carotic cannulation, D) VA
ECMO thoracic cannulation. Reproduced from: Gaffney AM, Wildhirt SM, Griffin MJ, Annich GM, Randomski MW.
Extracorporeal life support. British Medical Journal. 2010;341:982-986.
without having wide spread studies for the previously mentioned adverse events. A study published in early 2022 highlights these knowledge gaps, as well as the debate between
experts and the use of ECMO in CARDS due to significant
complications, such as increased bleeding risk and intercranial
hemorrhage (ICH).7 Due to the nature of the hypercoagulable
state and formation of microthrombi in COVID-19 patients,
the Extracorporeal Life Support Organization recommended
that institutional anticoagulation guidelines be followed with
the option to increase the anticoagulation intensity to potentially prevent the blood clots from catching in the oxygenator.
This study tried to determine if the anticoagulation recommendations were the primary reasons for increased bleeding risk
and ICH incidence, but were unable to determine if it was the
cause or if it was the undetermined pathophysiology of the
disease. However, they found that CARDS patients receiving
VV-ECMO had a six-fold increased risk of ICH compared to
a control group with ARDS due to a non-SARS-CoV-2 viral
infection, demonstrating that there are still questions about the
use of ECMO for COVID-19 patients, including the level of
necessary anticoagulation.7 The risk of potential bleeding from
ECMO use in critically ill COVID-19 should be considered
before cannulation.
The swift emergence of the SARS-CoV-2 virus and the severe lung disease caused by COVID-19 drove physicians and
scientists to develop treatment guidelines that employed the
use of ECMO. Because many COVID-19 patients have respiratory distress presenting similarly to traditional ARDS, and
because ECMO use saw relative success during the influenza A
H1N1 pandemic, the use of ECMO as a life support in patients
with severe CARDS was utilized early in the pandemic. As
it became clear that COVID-19 patients were presenting with
hypercoagulable states, the associated thrombotic risks of using ECMO were explored. The use of ECMO as a treatment for

patients with COVID-19 suffering from severe ARDS needs
to be continually evaluated to determine whether the improvements in care eclipse the associated risks and potentially fatal
adverse events.
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The First Pig-to-Human Heart
Xenotransplantation

By Eric Teicher, Class of 2025
RESEARCH SPOTLIGHT

T

his past January 7 marked a major milestone in the field
of surgical transplantation: surgeons announced that they
had performed the first transplant of a pig heart to a human
recipient. Although many questions remain, including the
prognosis of the patient, this marks a major milestone in the
field of xenotransplantation. The surgery was performed by an
expert team at the University of Maryland School of Medicine.
To achieve this historic moment, the pig heart required many
genetic changes for the organ to function successfully in the
patient. This surgical research spotlight will detail the exact
mechanisms by which this was performed.
The procedure stood to be the first time a pig organ was
transplanted into a living human. However, the prospect of
transplanting porcine organs into humans is not new. Previously in 2021, surgeons at New York University Langone Health
center transplanted kidneys from a similar line of genetically
modified pigs into humans with no functioning brain activity.
As a result, the organs were viably sustained using a ventilator
on the deceased patients. Other research has focused on xenotransplantation into non-human primates, yet researchers are
optimistic this pig-to-human heart transplant will open many
doors for the future of clinical research.
The transplant recipient was 57-year-old David Bennett.
Bennet had advanced heart failure and ventricular fibrillation.
He was deemed ineligible for a human heart transplant according to University of Maryland School of Medicine listing
guidelines due to prior treatment nonadherence. Thus, the team
sought a “compassionate use” authorization from the Food and
Drug Administration (FDA) to give Mr. Bennett a heart from a
genetically modified pig.
The primary concern with xenotransplantation— similar to
human transplantation— is immune rejection in the recipient.
A total of 10 genes were modified or added to the pig cell line.
First, 3 genes that produce sugars on the surface of the pig cells
were knocked out. These antigens would typically result in
recognition of the pig cells as foreign. Additionally, researchers genetically added a total of 6 additions of human genes
to the pig: 2 anti-inflammatory genes, 2 genes that promote
normal blood coagulation, and 2 other regulatory proteins that
downregulate the antibody response.
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Residency Interviewing in the Zoom
Era

By Jose Arriola, Class of 2025
FEATURES

The final gene deletion removed a growth hormone to prevent any abnormal growth once the heart was implanted into
the donor. The researchers wanted to mitigate the possibility
of heart failure by preventing any additional growth of the already innately larger pig heart.
Finally, to prevent rejection after transplant, Mr. Bennett
was given a novel, experimental antibody immunosuppressant
called KPL-404. Typical immunosuppressants would not be as
effective given the strong antibody response against the transplanted organ. KPL-404 is an anti-CD40 immunosuppressant,
meaning that it binds to a specific receptor called CD40 that
suppresses the activity of antibody-producing B cells, which
also prevents T cell activation. Prior to transplantation, the
heart was bathed in a circulating bath, including water, adrenaline, cortisol, and cocaine as part of the priming process prior
to transplantation.
The University of Maryland transplant team has said the
surgery went well and “the heart function looks great.” However, despite all efforts to keep Bennet alive, he passed away
on March 8th. The University of Maryland did not report on
an exact cause of death but reported his condition had been
deteiorating since days earlier.
Although most of the prior research in xenotransplantation has
involved transplantation into baboons, researchers state that it
is important to study the transplants in humans given the vast
differences in antibody profiles between the species. Non-human primates often have antibodies that humans lack, making
it difficult to predict a response. Although the FDA has only
authorized this single transplant pertaining to Mr. Bennett’s
case, the team is optimistic that future clinical trials, hopefully
in humans, would result in an unlimited supply of donor organs. If successful, the medical landscape would be changed
forever.
References
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Pig-to-Human Heart Transplant.” Science, https://www.
science.org/content/article/here-s-how-scientists-pulled-firstpig-human-heart-transplant.
Reardon, Sara. “First Pig-to-Human Heart Transplant:
What Can Scientists Learn?” Nature News, Nature Publishing Group, 14 Jan. 2022, https://www.nature.com/articles/
d41586-022-00111-9.

T

his is the second year in a row in which residency
programs conducted virtual interviews as a result of the
COVID-19 pandemic. This meant swapping their hospital
tours for YouTube videos or providing Uber Eats gift cards
in lieu of lunch sessions. Similarly, 4th year medical students
needed to adapt to this new situation. From an outsider perspective, it may seem these changes are doable and reasonable for the time being. However, there is evidence suggesting that these changes might be more permanent. A recent
survey showed that 56 General Surgery program directors
(PDs) agreed that virtual interviews are less expensive. In
fact, 40 out of those 60 agree that they will adopt both virtual
and in-person interviews in future cycles.1 On the other hand,
another study showed that 45% of surveyed PDs in other
fields disagree that the 2022/2023 interviews should be virtual
regardless of COVID-19.2 This aligns with a study from the
University of Texas which found that medical students still
favor in-person interviews.3 Due to this conflicting information, we decided to explore this dichotomy.
Pro: The cost of interviewing for residency has been highly
reduced
The Associarion of American Medical Colleges (AAMC)
has estimated that a student spends around $4,000 during an
in-person residency interview cycle. In fact, those same estimations suggest the amount can even be as high as $13,225.4
However, expenses such as travelling, meals and lodging are
eradicated in the virtual setting. Saving this huge sum of money is advantagous for 4th year medical students. According
to a study done with 2021 urology applicants, the amount of
money saved was around $2,198 in travel costs per applicant.5
Pro: Planning interviews is easier
Another advantage of online interviewing is the ability to
prepare and plan an interview more easily. During interview
season, 4th year medical students are still participating in
clinical rotations; hence, there is a whole science behind
scheduling interviews. Generally, students schedule interviews during the small vacations, but sometimes they need to
ask clerkship directors for additional days off. Furthermore,
sometimes students need to group interviews geographically
to avoid multiple transcontinental trips. Zoom meetings allow
students to avoid these hassles and focus more on practicing
for the actual interview.

Con: You are not able to showcase your true self
One of the main disadvantages of online interviewing is that
you do it behind a screen. This can cause different problems
such as the inability to properly use body language. This can
be worrisome, considering some studies suggest nonverbal
behaviour can account for around 55% of effective communication.6 In consequence, online interviewing also makes it
hard to portray one’s personality correctly as it is sometimes
more difficult to form a connection with the interviewer.
Interestingly, one of the medical students we interviewed did
not find these issues too worrisome. In fact, she commented
that when practicing for interviews with her home institution,
she focused more on setting up the correct lightning and
Zoom background. While being able to showcase one’s true
self may be more challenging during online interviews, there
are other issues the applicants needed to consider in these
virtual times.
Con: It is difficult to assess the residency program
The same way it is hard for students to express themselves to
programs, it is difficult for students to fully assess a program’s positives and negatives. In fact, some programs decided to shift their budget from pre-interview dinners and hospital tours to creative media solutions, i.e., videos, websites,
etc.7 While these help medical students in getting to know the
program, it does not allow them to truly gauge the residency
experience. Students need to choose their top choices based
on how well they felt the online interview went, as well as,
how much they learned about the program and the city from
the screen. As one of the interviewed students mentioned: “It
does make it harder to decide how to rank programs in cities
that I’ve never been to .”
References:
1.Rajesh A, Asaad M, Elmorsi R, Ferry AM, Maricevich RS. The virtual interview experience for
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An Interview with
Dr. Andrew
Newman

it worked out well and the patient doesn’t, that’s a problem,
that’s a real problem.

INTERVIEW

By Ari August, Class of 2025
and Gregory Whitehorn, Class of 2025
Dr. Newman is a Clinical Assistant Professor of Surgery in the Division of Plastic Surgery. He received his Bachelor of Science
from the College of William and Mary and attended medical school at The University of Virginia School of Medicine. He completed consecutive residencies in General Surgery and Plastic Surgery at The Hospital of the University of Pennsylvania. Dr.
Newman specializes in microsurgery. He is certified by the American Board of Plastic Surgery and is a Member of the American
Society of Reconstructive Microsurgery.

W

hat led you to pursue a career in surgery?
I was super psyched to go to my medicine rotation.
I was in med school at UVA…I dove headfirst in–I loved it. I
kind of thought, “Huh, maybe I’m going to go into the medical
side of things.” I did some MICU and loved that, “Maybe I’m
going to go into intensive care.” I went into third year and I
was like, “That’s cool, I like that! Well, that’s neat too.” I did
rule some things out, but I guess that’s the way I ended up
approaching it; not “This is what it’s going to be,” but “This
is what it’s not going to be.” And then surgery came along towards the end. I just had more of a positive feeling in the operating room than I did anywhere else. So if I had to pin it, it’d
be on what the feeling is in the operating room.
What are some of the most rewarding parts of what you do on
a daily basis?
My practice is in breast reconstruction so the bulk of my patients are breast cancer patients. Breast cancer is unfortunately
an incredibly common disease. From a plastic surgery standpoint, we share a fairly condensed and emotionally poignant
process with that patient. [The standard breast cancer patient]
is diagnosed and they’ve already seen their gynecologist…a
breast surgeon, a medical oncologist, they’ve maybe seen a radiation oncologist, and then they see us. They’ve had a ton of
visits, everything is a bit of a whirlwind, and it’s hard because
there’s a lot of different treatment options. It’s just choice after
choice and it’s overwhelming.
Our time course is fairly short, so I get to see them through
the reconstruction process which can go up to a year on average, with maybe a revision. Then we get to say goodbye. It is
such a positive experience, I can’t tell you how many times
I’ve been really deeply, earnestly thanked for what I’ve done
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for that patient. That last visit is powerful for me. I feel super
lucky, I feel super appreciated, and I guess you come to figure out a little more clearly what value you’re adding to the
patient’s overall experience. The more time I spent with these
patients the more I’ve come to realize that what I’m doing isn’t
saving lives but it’s improving lives. And it’s improving them
for many people in a pretty profound way. That moment especially, that farewell visit, is sort of the high point for me
emotionally in what I do.

“...that farewell visit, is sort of the high point
for me emotionally in what I do.”
What inspired your research on the aesthestics of limb reconstruction?
It was interesting to look at aesthetics in limb reconstruction because that’s a scenario where you wouldn’t really think
about it, right? You’d say “Gosh, aren’t you just sort of happy
that you’ve got a closed healed soft tissue below and a healed
fracture underneath and you can walk on it?” We found that a
lot of patients weren’t just happy with that, and we shouldn’t
stop there either. We’re getting better at limb salvage and we’re
getting better at soft tissue reconstruction. Now that patients
are functional...and now they’re walking...ok now they’re
wearing shoes again...now they’re pain-free. How can we continue to make this better? Those kinds of things push you.
That’s something that I’ve found challenging about plastic
surgery: our results are right there in front of your eyes. This
is different from some surgical fields in that the patient’s interpretation of the outcome is a giant part of what we do. If I think

How do you balance empathy for the patient with methods to
prevent emotional burnout?
I think plastic surgery gives you a fairly low toll of emotional burnout. This is part of why I ended up where I ended
up. I had a hard time with cardiac surgery for what you just
said: emotional burnout seemed just inevitable for me. I was in
my second year of residency, and I had a three month stretch
of cardiac ICU. The outcomes can be challenging in something
like that, so emotional burnout ended up directly informing my
decision to say, “No, I can’t do this.” You have to think about
how you deal with complications because they’re going to
happen, and they’re going to happen again, and again.
The complications I see with my patients I do take very
personally, and I’m probably not the best at it. But it made
me realize I made a really good decision because if I’m having a hard time with some of these complications I just never
would’ve been able to deal with something like cardiac surgery.
Something I really liked in surgery when I was a med student is when we went to M&M. I really liked the sort of directness of surgical M&M and that, “Let’s talk about our mistakes,
let’s face them, let’s not avoid confronting them.” I think ultimately to get better we are going to have to look very critically
at what we’ve done and how we can make that better. I liked
that as a student–and I think that’s been something important
to ultimately avoid emotional burnout.

“You have to really love what you do.
There’s no substitute for being enthusiastic about
what you’re learning and what you’re striving to
do.”
How do you maintain work-life balance?
[laughs] Work-life balance is just a mess. I heard somebody
answer that question by laughing and saying, “You need to
drop the distinction between your work and your life and you
just need to let them kind of get like this: [interlocks fingers].”
Which on the one hand makes my blood pressure go up, but
on the other hand it allows you to stress a little bit less about
time management. If I let go of that micromanaging, then it’s
a little bit easier.
I have two kids who are almost eight and almost five. My
wife, Jane, is a pediatrician. We do talk a lot about balance,
but I don’t have any secret for it. It’s a challenge no matter
what we’re going to go into, and I think some people choosing
surgery may wonder, “Is [the time commitment] a potential
negative for my career choice?” I don’t think that should be a
primary driver of what you go into because [every profession
is] going to be fairly busy. Ultimately what type of person you
are, more so than the hours, is going to determine what you
decide to go into.

What is your advice for students looking for their right path in
medicine?
There are two points I want to talk about when people are
thinking about choosing a path. One: being a medical student
on a surgical rotation can be a bore because you might end up
seeing the same two or three procedures over and over again.
While that’s useful as a resident because you’re going to need
the physical reps to get good at that procedure, as a medical
student you’re either going to be observing or doing something
fairly basic like holding a retractor. If you don’t have a good
conversation or it’s not a good vibe, that can get really boring.
When I was a medical student, I was the laparoscopic camera
driver on a bariatric rotation so I saw umpteen-thousand gastric bypasses and I held the camera and didn’t hold it well. I
had to figure out, and every medical student who goes into surgery has to do this, “Do I think I’m really going to like being
the person across the table from me? Because I don’t really like
doing what I’m doing right now.”
The second point I wanted to make is that I probably put
too much importance into the relationship I had with a mentor
early on. He was a cardiac surgeon and a great medical student
advocate, and those two things don’t often coexist. He got me
involved with the team and the open cardiac cases, which was
really cool. I thought, “I’m going to go into surgery, and I’m
going to go into cardiac surgery.” Once I went into residency
at a different place and that person was gone, I realized, “Oh!
I sort of just wanted to be around that person, not necessarily
do heart surgery.”
What kind of qualities do you think are important characteristics of a successful surgeon like yourself?
First and foremost, you have to really love what you do.
There’s no substitute for being enthusiastic about what you’re
learning and what you’re striving to do because it’s going to
take time no matter what you pick.
In looking at surgical residency, one habit that a lot of surgical residents develop later in their residency is meticulously
documenting how to do a particular procedure. For me, that
was a little notebook. I didn’t really start keeping one until
towards the end of residency, and I was like, “Gosh, I’ve gotta remember this!” But that was enjoyable for me to do, that
didn’t feel like work, it was sort of fun to kind of piece all that
together. If work becomes uninteresting, then I don’t care what
your work ethic is, eventually you will burn out. This is the
moment you do your best to figure out an area that will keep
you excited and keep you engaged.
General surgical residencies are going to take a long time,
but you’re not picking something so you are happy in five
years–you’re picking something so you are happy in fifteen
years. There’s going to be such a long period of time for you
to practice whatever your field of choosing. I can’t overstate
this: it’s going to be a long time–in a good way–but man, don’t
sweat the extra year or two or three that it takes if that’s where
you want to go.
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Lung Transplantation for Patients
with Severe COVID-19 Pulmonary
Disease

By Marisa Joel, Class of 2024
REVIEWS

A

s of January 2022, there have been approximately 60
million confirmed cases of the coronavirus disease 2019
(COVID-19) and nearly 850,000 COVID-19 deaths in the
United States.1 The symptoms of COVID-19 range from those
of a minimal upper respiratory tract infection to severe respiratory failure with multiple organ failure.2 In patients with severe disease, a robust host immune response mediated by both
cytokines and inflammatory cells plays a major role in lung
destruction. Severe COVID-19 lung infections may result in
acute respiratory distress syndrome (ARDS) and pulmonary
fibrosis with characteristic pulmonary ground class opacification on CT scan.3
Lung transplantation is a life-saving treatment for a variety of end-stage lung diseases. The indications for lung transplantation are usually due to end-stage lung diseases, like
pulmonary fibrosis. Lung transplant, however, is infrequently
considered for patients with ARDS attributable to infectious
causes.4 Significant dysfunction of other vital organs, such as
that seen after severe COVID-19 infection, poses potential
contraindication to lung transplantation.5 Lung transplant (LT)
after severe lung damage due to COVID-19 infection represents unexplored territory.
Several concerns limit the use of LT as a therapy for patients with severe ARDS secondary to COVID-19. First, it is
possible that the superinfecting pathogen might recur in the allograft. Second, severe vascular and pleural damage secondary
to COVID-19 infection might create technical barriers to the
transplant procedure. Fibrotic lung disease, such as that due to
COVID-19, has been shown to make the vascular anastomosis
technically more challenging.6 This subsequently increases the
time of tissue ischemia, further worsening outcomes. Third,
most patients with critical COVID-19 have likely endured exceedingly prolonged hospitalization, immobilization, compromised nutritional status, and treatment with corticosteroids and
neuromuscular blockade, all of which lead to marked deconditioning and subsequent difficulty in rehabilitation following
the LT.7 Lastly, it is uncertain whether the lung is capable of
repairing itself after severe COVID-19, in which case consideration must be taken to understand the long-term outcomes
associated with spontaneous recovery as compared to LT. Experts agree that 4 weeks is considered an absolute minimum,
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and more often wait for 8+ weeks, before seriously considering
transplantation. Anecdotally, cases with CT evidence of fibrosis have subsequently improved without transplant intervention.8
Despite these concerns, however, there have been successful LTs in patients who experienced COVID-19 pneumonia in whom full lung recovery was unlikely without surgical
intervention. The earliest reports were those in China, suggesting that LT may be an option for COVID-19 patients with
Polymerase Chain Reaction (PCR)-negative results.9,10 Later
cases in the United States expanded upon Chinese reports by
demonstrating that LT can be completed in patients with positive RT-PCR results, provided that Vero cell cultures confirm
non-infectivity.11
A case series of successful LTs at Northwestern University
Hospital found that lung disease after severe and prolonged
COVID-19 infection–associated ARDS shared pathological
and molecular features with pulmonary fibrosis requiring LT,
suggesting LT may be the only option for survival in these
patients.7 Based on their experiences with successful LTs, researchers made the following recommendations: (1) bilateral
rather than single LT to decrease subsequent development of
pulmonary hypertension, (2) allowance of sufficient time to exclude possible spontaneous lung recovery, (3) patient involvement in the transplant decision when possible, (4) requirement
of two negative PCR test of bronchoalveolar fluid.7,12
Given the many considerations and complex interplay
between COVID-19 infection and various comorbidities, the
decision to proceed with LT in the cases of severe pulmonary
disease is not a clear path. King et al. have proposed a potential diagnostic algorithm for the evaluation of inpatient lung
transplant candidates with COVID-19, shown in Figure 1.13
Khozani et al. have suggested ten considerations14 that should
be taken into account during a COVID-19 patient evaluation
for LT candidacy: (1) patients must not be older than 65, as cases of older patients showed poorer outcomes such as increased
length of stay, 1 and 3-year mortality, and risk of postoperative
infection due to declining immunity.15 It is important to note
that most COVID-19 patients admitted to the ICU are older
than the maximum age limit for LT16; (2) Candidates must
have single-organ dysfunction only, as the feasibility of LT for

Figure 1: Algorithm for Evaluation of Inpatient Lung Transplant Candidates with COVID-19.
Reproduced from: King CS, Mannem H, Kukreja J, et al. Lung Transplantation for Patients With COVID-19. Chest.
2022;161(1):169-178. doi:10.1016/j.chest.2021.08.041
COVID-19 patients with multiorgan failure requires additional consideration; (3) Spontaneous recovery must be ruled out
by waiting the minimum 4 week timeframe prior to proceeding with LT; (4) There must be radiological documentation
of refractory lung disease; (5) The patient must be informed
and able to discuss transplantation; (6) Patients must receive
adequate physical health care while on the waiting list17; (7)
Patients should be eligible for standard transplantation criteria
such as sufficient body-mass index and absence of other notable comorbidities, including severe heart disease18; (8) Recent
SARS-CoV-2 PCR result should be negative, as the post-surgery fatality rate is remarkably higher for patients who tested
positive for infectious diseases, even in asymptomatic cases16;
(9) The surgical center should be qualified in performing highrisk surgeries; and (10) Wide donor pool should be accessible
to qualified surgical centers to maximize survival chance of
patients on the waiting-list.19
While there have been reports of promising outcomes,
lung transplantation for treatment of severe pulmonary disease caused by COVID-19 is far from a panacea. Even studies
reporting positive LT outcomes for patients with irreversible
lung disease call for more research to determine the long-term
outcomes of LT for patients with severe COVID-19.4,7 LT for
COVID-19 should be limited to patients requiring mechanical
ventilation or ECMO despite several weeks of care in the ICU,
advancing disease severity, radiographic signs of irreversibility, and a high risk of developing life-threatening complications. Though it may prove life-saving, the decision to proceed
with LT for COVID-19 infection is not without risk and should
be made by a multidisciplinary team following sufficient time
to rule out spontaneous recovery.
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Risk Factors for Five-year Mortality
After Carotid Endarterectomy

By Taylor Haddad, Class of 2023
RESEARCH SPOTLIGHT

A

therosclerotic disease is a leading cause of modern-day
morbidity and mortality. Carotid stenosis, caused by a
build-up of cholesterol plaque, commonly burdens the carotid
artery bifurcation and is among one of the most studied vascular pathologies. Clinically, carotid stenosis may manifest as a
transient ischemia attack, stroke, or other neurologic sequelae,
however many patients experience asymptomatic disease that
is found incidentally. Current management guidelines recommend carotid endarterectomy (CEA) for asymptomatic carotid
stenosis if occlusion is greater than 70% in patients with acceptable surgical risk. Yet, depending on patient demographics
and comorbidities, the risk of 5-year mortality for this population can reach up to 70% following CEA.1
Using the robust Vascular Quality Initiative (VQI) online
database, Blecha, DeJong, & Carlson (2022) explored risk factors for 5-year mortality in asymptomatic patients following
CEA. Historically, studies have demonstrated the benefit of
CEA versus medical management in asymptomatic patients,
however recent research shows the implementation of modern
medical management has proven to decrease risk of stroke in
this population. Notably, the authors underscore that the benefits of elective CEA for asymptomatic disease requires a long
survival. Therefore, this research aims to more precisely pinpoint risk factors in surgical candidates to assist with reducing
unnecessary surgeries when medical therapy may be a more
suitable option for asymptomatic disease.
This study is a retrospective review of 30,615 patient records
from the VQI database. Inclusion criteria consisted of documented survival status, complete data on all of the study variables, and asymptomatic neurological status. Of the patients
that met study parameters, 5,414 (18%) experienced mortality
within 5 years post-CEA. Variables that were studied include
demographics (gender, age, race, body mass index), past medical history (specifically assessing history of congestive heart
failure, diabetes, chronic obstructive pulmonary disease, endstage renal disease and dialysis status, active coronary artery
disease, and prior myocardial infarctions) prior surgical history (with a focus on coronary artery bypass or percutaneous
artery stenting), and medical therapy (aspirin, P2Y12 antagonists, statins, and beta-blockers). Importantly, this study also
assesses social determinants of health such as housing status
(homelessness vs. assisted living vs. home) and social factors
(e.g., smoking).
Of the variables studied several identified risk factors and
their associated odds-ratios include: housing status other than
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home (2.1) > black race (1.3) > age (1.04) > female gender
(0.99). High risk comorbidities include hemoglobin less than
10mg/dl (2.1) > history of congestive heart failure (1.9) > history of COPD (1.8) > BMI under 20kg/m2 (1.7) > history of
lower extremity major amputation (1.5) > LE bypass = history
of neck radiation = renal insuﬃciency = smoking history = diabetes (1.3). It was also found that taking statins and aspirin
at the time of surgery was protective against 5-year mortality.
Beta blockers and P2Y12 inhibitors were not found to be protective. The results were formulated into an advanced mortality
risk calculator. With one-point for renal insuﬃciency, history
of smoking, diabetes mellitus, history of radiation, history of
lower extremity bypass or venous intervention, black race, and
major amputation. Two points are added for BMI under 20 kg/
m2, COPD, and history of congestive heart failure. Three points
are allotted for hemoglobin under 10, living status other than
home, age greater than or equal to 80 years old. Five points are
given for end stage renal disease on dialysis. The authors highlighted as the risk calculator score increases, so does the risk
for 5-year mortality following CEA for asymptomatic disease.
Patients with a score of zero are at a 5% risk 5-year mortality,
compared to those with a score of 3 and nearly a 20% risk and
those with a score of 8 with slightly over 40% risk.
The greatest risk factors for 5-year mortality in this study
were hemoglobin less than 10mg/dl and 2.1 and housing status
other than home, both demonstrating odds-rations of 2.1 and
reaching statistical significance with p-values <.001. The significance of housing status influencing mortality highlights the
importance of socially responsible surgical care that assesses all
spheres and variables of a patient’s life that may impact success
both in and out of the hospital.
These findings offer novel insight into the long-term risks
of CEA in patients with asymptomatic carotid stenosis. Importantly, this work emphasizes the need to screen asymptomatic
patients prior to surgery, fully assessing their demographic, social, and medical risk factors that may contribute to their risk
of 5-year mortality following the procedure. This study’s novel
risk calculator will lead to thorough screening and better inform pre-surgical risk stratification and allow patients with asymptomatic carotid disease to make a more informed decision
regarding their care.
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Interview with
Dr. Scott Cowan

The COVID pandemic has brought the issues of fatigue and
burnout to the forefront of medicine and now are a large focus
of health systems. Not only has COVID impacted the mental
and physical wellness of our health care staff, COVID has also
created a large staff shortage in hospitals across the country
which introduces a new component of risk. Jefferson has a
robust, multitiered wellness program that has been designed
to provide staff with much needed wellness resources. Studies have shown that burnout and fatigue have definitely been
associated with medical errors and the goal is to help reduce
these issues to further improve the quality and safety of care
provided to our patients.

INTERVIEW

By Anjali Patel, Class of 2023
and Amiti Jain, Class of 2025

D

r. Scott Cowan is a trained general and thoracic surgeon who now serves as the Medical Director for
Enterprise Risk and as the Enterprise General Surgery Quality lead. He completed medical school and
general surgery residency at Jefferson before completing his thoracic surgery fellowship at Massachusetts
General Hospital. After training, Dr. Cowan worked as a general thoracic surgeon at Penn Medicine for
3 years until returning home to Jefferson in 2010. Here, he was exposed to the field of quality and safety
and was inspired by mentors including Dr. David Nash and the thoracic surgery legend, Dr. Herbert Cohn.
Dr. Cowan received his Master’s degree in Healthcare Quality and Safety through the Jefferson School of
Population Health and then functioned as the Vice Chair for Quality in the Department of Surgery while
he was clinically active as a thoracic surgeon – a challenging feat. Dr. Cowan also served as Vice President
and then President of the Pennsylvania National Surgical Quality Improvement Program (NSQIP) Consortium and played a role in developing the City of Philadelphia Perioperative Opioid Prescribing Guidelines.
I just wanted to begin by recognizing the Gibbon Surgical Society for all of the incredible work that has been accomplished
in the past and all of the great work that is currently underway.
I had the true pleasure of serving as the Faculty Advisor to the
Gibbon Surgical Society for many years and miss collaborating
with our Gibbon medical students on projects and activities.
How much of your current job involves interacting with
patients versus administrative duties?
I have transitioned to 100% administration over the past few
years given my strong interest in risk management and my
background in quality and safety. This transition has provided the incredible opportunity to learn from the true leaders
in these fields including Drs. David Nash, Jonathon Gleason,
Herbert Cohn, Joshua Clark, Lisa Ramthun, and many others.
It has been an exciting journey.
In situations resulting in patient harm, how are underlying
causes determined?
In terms of patient harm related to medical errors, there was
a landmark publication by the Institute of Medicine (IOM) in
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1999 that you will see referenced in many talks and writings
about quality and safety that changed the way we think about
medical errors and adverse events. The authors of the IOM report, “To Err is Human: Building a Safer Health System” noted
that most errors are systemic in the healthcare system and that
the majority of these errors can’t be resolved at the provider
level.1
Jefferson’s approach to errors involves a very well-structured
error classification system that follows the root cause analysis
(RCA)2 approach that was implemented largely by Dr. Oren
Guttman and other Enterprise leaders. The approach allows for
a rapid categorization of the event followed by a systematized
process that is used to identify the underlying cause of these
events. The final step involves developing and implementing
an action plan to prevent these events from happening again.
RCA2 looks and feels very different from our previous processes and has been functioning extremely well in our enterprise hospitals.
Can you touch on how physician burnout and fatigue potentially contribute to system failures?

I have had the privilege of working with wellness leads from
our Jefferson Enterprise hospitals in implementing a peer support program call RISE (Resilience in Stressful Events). Although system errors are evaluated by RCA2 following adverse
events, attention is rarely focused on the emotional impact on
our healthcare colleagues that are involved. Peer supporters are
trained to provide psychological first aid (PFA) to Jefferson
employees following difficult hospital-related adverse events.
The Jefferson RISE Program started at Jefferson Abington
Hospital and is now live at nearly all enterprise hospitals with
a plan to go live at Einstein Hospital in July, 2022. RISE is a
very proactive program and, to date, over 200 employees have
received peer support following adverse events.
Since the COVID pandemic began, there have been countless changes in healthcare. What’s your perspective on telehealth appointments from a risk standpoint?

practices around central lines.
Many of us have read and highly regard Atul Gawande’s book, The Checklist Manifesto, detailing how even
the most competent surgical team can benefit from using
checklists. How are surgical checklists and timeouts used
at Jefferson?
First of all, I love Dr. Gawande’s book. I have a copy of The
Checklist Manifesto right next to me on my bookshelf. I love
the idea and utility of using checklists in many areas of medicine and surgery particularly as they apply to time outs. There
are great data to support the use of surgical checklists.2 The
real opportunities now lie in how to best integrate these checklists into our electronic medical record and use data entered
into our EMR to audit compliance with checklist elements. At
Jefferson, the quality and safety teams, risk management and
many of our providers work closely with our EPIC optimization team and IT colleagues to leverage technology to increase
data transparency and make data usable at the patient’s bedside. Over the past 2 years, an incredible quality, safety and
experience program was created at Jefferson called OnPoint.
OnPoint includes a Safety Management System, Quality Management System, Patient and Family Centered Care, as well
as the OnPoint Reporting and Feedback/OnPoint Insights program.
Any message you’d want to convey to folks reading this
interview?

Great question. All hospital systems had to pivot quickly to
accommodate the high-volume of telehealth visits during the
COVID pandemic. Prior to the pandemic, our IT leadership at
Jefferson had developed and implemented a strong telehealth
program that required some optimization and proved successful throughout the COVID pandemic. Telehealth does introduce a variety of new risks including diagnostic errors, patient
access issues, patient confidentiality and documentation requirements and the risk management team works closely with
IT leads to help reduce risk with these processes.

As a student, I never realized all of the opportunities to pursue interests in areas that are, in a sense, non-traditional when
you think of medicine. There are many paths you can go down
to enhance your career and create a satisfying and rewarding
experience. There are also opportunities to become involved
regionally and nationally in societies related to your area of
practice and interest. Even as an attending who completed
training 15 years ago, I still feel like a student and enjoy learning more about surgery, medicine, quality and safety and risk
management every day.

We know that one of the prominent projects run by the Enterprise quality and safety leads is the initiative to decrease
CLABSI (Central Line Associated Bloodstream Infections). What has our health system done to reduce these?

You have a lot to look forward to!

CLABSI’s can be life threatening infections with an associated mortality of 12-25%. Best evidence shows that CLABSI’s can be reduced using central line bundles which include
best practices for line insertion, maintenance and monitoring.
Through a coordinated multidisciplinary effort across the Jefferson Enterprise, the CLABSI reduction team efforts resulted
in a decrease in the standardized infection ratio (SIR) by 14%
which is an incredible achievement. There is an ongoing effort
to reduce this complication and a CLABSI Temporary Action
Group (TAG) has been created to focus on standardizing best
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GEN SURG 101:
The J-Pouch

2. J Pouch Creation:
Small bowel is mobilized from its mesentery to the third part
of the duodenum. The terminal 30-40 cm of ileum is used for
the creation of the pouch, and is folded into two segments,
each 15-20 cm long. The two segments are then anastomosed
side to side using a GIA stapler creating a large pouch lumen.
At the apex of the pouch, a longitudinal enterotomy is made
which serves to facilitate anastomoses between the two ileal
loops and connects to the anus. The blind end of pouch is stapled closed. 5, 6,7

By Leah Iosif, Class of 2024
GEN SURG 101

T

he idea of an ileal-anal anastomosis was first developed as
an alternative to an ostomy. In 1933, Rudolph Nissen was
the first physician to attempt an anastomosis between the ileum and anal sphincter, but unfortunately was unsuccessful.
Following Nissen, between 1941 and 1947 various physicians
began experimenting with alternative methods of ileo-anal
anastomosis. In Philadelphia, PA, during 1952, Valiente and
Bacon developed the idea of a three-loop ileal pouch with an
efferent spout that was sutured to the anal sphincter. While
they noted anal sphincter control was maintained, the test subjects all suffered from severe post-operative complications that
proved fatal.1,2
In 1978, Sir Alan Parks and Mr. John Nicholls successfully
put together the idea of an ileal anal anastomosis and 3-limbed
ileal reservoir, as they are the first to describe an ileal pouch
anal anastomosis (IPAA). Parks and Nicholls created an S
pouch, using 3 loops of small intestine and a hand-sewn anastomosis between the pouch and the anus.2
Today, the favored approach is the J-pouch which was created by Dr. Utsunomiya. He built on the previous methods
and developed the concept of using 2 loops of small intestine
to make the J-pouch. The basis of the J-pouch was designed
around 2 main concepts, a lateral anastomosis between the
looped terminal ileum and an anastomosis between the anal
canal and top of the ileal loop. Additionally, the use of a handsewn anastomosis has fallen out of favor for a stapled approach
which reduces the incidence of damage to the anal sphincter
and transition zone.1,3

Figure 6. Ileostomy reversal. Reproduced from: Sheedy, S.P., Bartlett,
D.J., Lightner, A.L. et al. Judging the J pouch: a pictorial review.

Fig. 1. J-pouch. Reproduced from: The Cleveland Clinic. J-pouch
surgery . The Cleveland Clinic website. https://my.clevelandclinic.
org/health/treatments/21062-j-pouch-surgery. Updated 2019.

Indications and Goal of Procedure:
The indications for the J-pouch procedure are: Ulcerative Colitis refractory to medical management, colorectal cancers requiring total abdominal colectomy and Familial Adenomatous
Polyposis (FAP). The aim of the J-Pouch procedure is to provide continence, avoid permanent stoma, prevent malignant
degeneration and cure disease. 4
The Procedure
1. Proctocolectomy:
A midline vertical incision is made and the sigmoid colon and
rectum are mobilized. The rectum is transected at the top of the
anal columns, making sure to cut 1-2 cm above the dentate line
which is important in the maintenance of continence. The mesentery of the descending colon is incised lateral to the inferior
mesenteric vein. Mobilization of the left side of transverse colon is done along Toldt’s fascia until reaching the inferior margin of the pancreas. Toldt’s fascia serves as a surgical landmark
in mobilization of the mesocolon. The greater omentum is then
dissected out. Dissection is continued until full mobilization of
the descending colon and splenic flexure is achieved. A right
colectomy is then performed first by freeing peritoneal attachments, once again following along Toldt’s fascia. Once mobilized, dissection is continued from the cecum, to the hepatic
flexure and ending with the transverse colon. 5, 6,7

Abdom Radiol 44, 845–866 (2019).

5. IPAA: Ileal Pouch-Anal Anastomosis
The anvil of stapler is placed through the enterotomy opening
at the apex of the J-pouch. This is secured with a purse string
suture. At the anorectal stump another purse string suture is
used, and with a trans-anal approach, the circular stapler is advanced. The stapler is fired, and this competes the IPAA. 5,6,7
Figure. 4 . J Pouch Creation steps. Reproduced from: Kirat, Hasan T,
and Feza H Remzi. “Technical aspects of ileoanal pouch surgery in
patients with ulcerative colitis.” Clinics in Colon and Rectal Surgery
vol. 23,4 (2010): 239-47.

3. Ileostomy Creation
The ideal site for stoma placement is typically within the rectus abdominus and beneath the umbilicus laterally. An area
of small intestine proximal to J-pouch is brought through the
skin and sutured into a stoma.5,6,7

nancy.ibdclinic.ca/Ibd-Surgeries. 2022.
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Figure 3. Showing point where rectum is transected (1-2cm above
dentate line). Reproduced from: Kirat, Hasan T, and Feza H Remzi.
“Technical aspects of ileoanal pouch surgery in patients with ulcerative colitis.” Clinics in colon and rectal surgery vol. 23,4 (2010):
239-47.

Common Complications:
Pouchitis; inflammation of the ileal reservoir; pelvic sepsis;
pouch failure; and small bowel obstruction.4,8
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Figure 5. Ileostomy and Stoma Creation. IBD Surgeries. Reproduced
from: Preconception and Pregnancy in IBD website. https://preg-

Figure.2. J pouch (left) and S pouch (right). Reproduced from Kirat,
Hasan T, and Feza H Remzi. “Technical aspects of ileoanal pouch
surgery in patients with ulcerative colitis.” Clinics in colon and rectal
surgery vol. 23,4 (2010): 239-47.

Contraindications to Procedure:
A complete contraindication to the procedure is patients with
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tutions have received formal mentorship training, are effective
and act as a platform to connect women surgeons across the
United States. Considering the shortage of female surgeons
currently, support must also come from willing male surgeons.
An example of successful male mentorship is The American
Thoracic Society’s program recognizing effective male mentors to female residents. To bridge the pay gap, recent initiatives by several organizations such as the Mayo Clinic now
offer identical salaries to men and women.7 Finally, in an effort
to be more mindful of women’s issues, many hospitals now
have dedicated lactation rooms. Changes over the last 20 years
came only as a result of the sacrifice prior women surgeons
made in order to establish themselves as equals in the operating room. It is because of their dedication, the obstacles which
were once walls are now merely hurdles.

By Diana Jimenez, Class of 2023
FEATURES

W

here are all the women in surgery? This question was
the headline of a 2019 Association of American Medical
Colleges (AAMC) article that outlined the years-long struggle in recruiting and retaining female surgeons. According to
the AAMC 53.7% of medical students are female.1 However,
the percentage of women in general surgery residency remains
disproportionately low with only 30% of women making up
surgical residents in 2020, up from 15% in 2000.2 In contrast
to surgical residencies, women make up 43% of internal medicine residency programs.3 In academic medicine women only
make up 19% of academic surgeons compared to 36% of internists. Additionally, female surgeons make up only 9% of
professors in medical schools, compared to 19% of internal
medicine faculty.4 Only 7% of surgical department chairs are
women compared to 19% of medicine department chairs.4,5
Furthermore, Elmore et al.6 found that women surgeons were
60% more likely to experience burnout and were more likely
to have symptoms of depression than their male counterparts.
According to current literature, residency training, mentorship
and professional fulfillment are the 3 biggest factors impacting
the careers of female surgeons.

Residency

From recruitment to program logistics, residency programs
should be continuously evaluated and improved to be consistent with current priorities including implicit biases and a
rigid schedule. Part of increasing representation of women
in surgical programs includes building programs that are not
only inclusive of women, but also understand the specific challenges they face during residency. According to Stephens et
al.7, women trainees experience less autonomy than their male
counterparts. The problem is prevalent with 6% of female
chief residents receiving the designation of needing “extensive
guidance” compared to 1% of their male coresidents. Pregnancy during residency is another unique stressor that is further
compounded by a challenging and inflexible training schedule.
A study of female surgeons who had children during residency
found women were likely to face difficulties surrounding work
scheduling, in addition to a lack of lactation and childcare
support.8 Forty percent reported seriously considering leaving
surgical training. A 2019 study found that 43% of residents
took less than 2 weeks of parental leave.9 In 2021, Kim et al.10
found only 35% of all female surgeons were able to have all
their desired children without assisted reproduction therapy as
compared to 57% of men.
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Mentorship

Mentorship is a double-edged sword for women. The small
number of senior female surgeons creates a mentorship burden as the growing number of residents and young attendings
struggle to find mentors whose experiences mirrored their
own. Mentorship and support not only play a role in successful
surgical training but also are crucial in the development of an
academic career and professional advancement. As a whole,
women represent only 19% of tenured professors, 12% of
department chairs, and 11% of medical school deans.11 With
a scarcity of mentors, innovative solutions that consider the
unique challenges faced by female surgeons must be developed.

Professional Fulfillment

Lack of representation, decreased autonomy, and suboptimal
guidance and support during training can have negative longterm effects on the career of women surgeons. A survey by the
Michigan Medicine Department of Surgery found that female
surgeons reported lower professional satisfaction compared to
men.12 Two well-studied aspects contributing to this finding include compensation and career advancement. Greenup et al.8
found that across the board, female surgeons make 8% less
than their male counterparts even when controlling for years
of training, subspecialty, faculty rank, and metrics of clinical
and academic productivity. Referrals, an important component
of compensation, also favors male surgeons. Dossa et al.13 reported male physicians were significantly more likely to refer
patients to male surgeons than female surgeons.
In contrast to compensation, career advancement and promotion is more difficult to measure and assess. In academic
medicine, advancement is closely tied to research and editorial
activities. Stephens et al.7 outlined differences in research funding, with junior faculty women receiving a median of $350,000
compared to the $889,000 men received even after controlling
for degree, years of experience, and institutional characteristics. In addition, men consistently receive more R01 grants
at all career stages and are more likely to have higher scores
on their renewal applications than women.14 The disparity in
funding could also explain why women are underrepresented
as primary investigators in scientific journals representing only
17% of last author publications in the top 25 surgery journals.15
In 2017 only 19% of those serving in high impact surgery jour-

Two Thomas Jefferson Uniersity Hospital residents perform a cholecystectomy.
2022. Courtesy of Jefferson General Surgery Residency Prgram,

nals were women.7 The lack of inclusion of women in editorial
boards came under a national spotlight when the Journal of
Vascular Surgery published an article about ‘unprofessional’
behavior in surgeons. The all-male authored and edited article
drew backlash for essentially grading the social feeds of surgeons, particularly women surgeons. In its statement announcing the retraction of the article, editors of the journal pledged
to increase the diversity of their editorial boards.16

Moving Forward

Renowned liver surgeon Dr. Nancy Asher once made the following remarks highlighting Dr. Olga Jonasson’s career as a
pioneering female surgeon: “Dr. Jonasson was the first to ask
where are all the women? This question focused our attention
on the pipeline, lack of female leadership, and decreased visibility at meetings. It forced us to think about how to attract
women in our fields.” Dr. Jonasson, who embarked on a surgical residency despite being told her choice was “absurd” by a
medical school dean, became the first female Chair of Surgery
at a major academic institution. Her accomplishments inspired
countless women surgeons that followed.
Though the outlined obstacles may seem daunting, advocates
within the field have made great strides towards recruiting and
retaining more women in surgical specialties since Dr. Jonasson. Since 2000 the percentage of female academic surgeons
has nearly doubled.2 Progress has also been made towards improving the lives and careers of the women already in surgery.
Mentorship, and specifically, trained mentorship-mentee relationships empower women within their practice to seek professional fulfillment. Programs like the University of Wisconsin’s
Entering Mentoring program, where 500 women from 39 insti-
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The Gibbon Surgical Society
The John H. Gibbon, Jr. Surgical Society (GSS) at Sidney Kimmel Medical College (SKMC) at Thomas
Jefferson University is a unique student interest group that has been working hard to increase interest in the
field of surgery among medical students for the last 38 years. The society has over 400 total active members
on a year to year basis, spread across the four-year curriculum. The GSS increases exposure and interest to
the surgical field through a unique blend of episodic and longitudinal programming that helps bring together students, residents, and faculty in an educational setting.
The crux of the GSS approach to bolstering medical student interest is early exposure. Over the years,
the GSS has run many programs specifically targeted at students in the pre-clinical curriculum to increase
surgical exposure, including overnight shifts on the trauma service, call with the organ procurement team,
and SCALPELS, a longitudinal surgical curriculum that runs concurrently with the pre-clinical curriculum.
There are also events that are available to all students. The GSS runs a quarterly journal club, which is led by
a surgeon at Jefferson in the field that is currently being studied by the second-year medical students. Many
surgeons take this time to not only educate the students in critical review of the findings of papers, but also
the underlying statistics that were used. The Philadelphia Surgical Symposium is the GSS’s signature event
each year. Students from all medical schools in the Philadelphia region are invited, and it is intended to be an
informative opportunity for medical students interested in surgery. There is an associated regional medical
student research poster session and competition during the event, complemented by presentations from a
faculty member from each school, ranging in topics from clinical experiences, to advocating for a particular
field of surgery, to hot topics in research.
While the COVID-19 pandemic has changed the landscape of medical education, the GSS has worked
tirelessly to create new and exciting programs to keep students engaged. Between moving some previously
established programming to a virtual format to starting new and innovative experiences including podcasts
and virtual anatomy sessions, the GSS board has ensured a robust experience for all students wanting to
become more involved with the surgery department at Jefferson.
The GSS was presented at the AAMC’s Learn, Serve, Lead 2017 conference as a model for an effective
medical student interest group. This journal, the GSR, is written, compiled, and curated by SKMC students
through the invaluable help and planning of the GSS members, and stands not only as a testament to the
involvement and hard work of the GSS, but also of the student body as a whole.
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